Science 37 Holdings Stock Price, News & Analysis

Science 37 Holdings, Inc. (SNCE) operates in the professional, scientific, and technical services sector, with a focus on testing laboratories and clinical research support. According to company disclosures, Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients and expanding patient access to clinical trials. The company emphasizes patient-centric and direct-to-patient models that allow participation from home or local community settings, rather than relying solely on traditional brick-and-mortar trial sites.

Science 37 describes itself as a leader in enhancing patient access to clinical trials and in expanding the reach of clinical research beyond traditional sites. The company is based in Morrisville, North Carolina, in the Research Triangle Park region, where it has established a corporate headquarters that serves as a hub for its operations and cross-functional teams.

Business model and core solutions

Science 37 states that it accelerates clinical research by combining technology, medical expertise, and operational capabilities to support clinical trial sponsors and contract research organizations (CROs). Its model is built around two primary solution categories that the company repeatedly highlights:

• Metasite™ (Virtual Site) – A virtual clinical trial site model that Science 37 describes as enabling universal trial access for patients. The Metasite™ is characterized as a Virtual Site that allows patients to participate in clinical trials from their homes or local community providers. It is powered by a proprietary technology platform and in-house medical and operational experts, with the goal of ensuring uniform study orchestration, regulatory compliance, and high-quality data.
• Patient Recruitment – A recruitment and enrollment offering that Science 37 makes available on a standalone basis or in combination with the Metasite™. The company reports that this solution is used to identify, recruit, medically qualify, and enroll patients without geographic restrictions, and to rigorously qualify patients before referring them to traditional sites when applicable.

Across its disclosures, Science 37 explains that these solutions are designed to expand the reach of clinical trials beyond the traditional site, increase access for diverse and geographically dispersed patient populations, and support sponsors that face enrollment and study conduct challenges, including in rare disease and complex therapeutic areas.

Direct-to-Patient Site and decentralized clinical research

Science 37 describes a Direct-to-Patient Site model that extends clinical trial reach beyond the geographic limitations of traditional sites by enabling participation directly from patients’ homes. The company reports that this site model leverages nationwide recruitment and 50-state medical licensure, and that it provides a range of site services such as investigator oversight, research-grade nursing, clinical research coordinator (CRC) support, and direct-to-patient logistics.

According to Science 37, this direct-to-patient approach facilitates faster enrollment, enhances trial accessibility, and supports the collection of high-quality data across studies of varying complexity. The company has highlighted its role as a key enrolling site in multiple Phase 2 and Phase 3 clinical trials, including rare disease and immunocompromised patient cohorts, where it contributed substantial portions of total enrollment and helped address under-enrollment challenges.

Regulatory inspections and quality focus

Science 37 reports that its Metasite™ and Direct-to-Patient Site models have undergone multiple inspections by the U.S. Food and Drug Administration (FDA). The company states that these inspections reviewed internal processes, technology platforms, data integrity, subject safety, protocol adherence, Principal Investigator oversight, and related documentation.

In these disclosures, Science 37 notes that the inspections have resulted in a “No Action Indicated” categorization, with no objectionable conditions and no Form 483 issued. The company presents these outcomes as validation of its ability to deliver high-quality, regulatory-compliant research in a decentralized or direct-to-patient format, and as evidence that its virtual site model can meet inspection-level standards for pivotal clinical studies.

Clinical trial applications and therapeutic areas

Science 37’s published case examples describe its participation in a range of clinical research programs. The company reports involvement in Phase 2, Phase 3, and observational studies across therapeutic areas such as hematology, hepatology, infectious diseases, central nervous system (CNS) conditions, oncology, and rare diseases. Specific examples mentioned by the company include rare disease trials in primary biliary cholangitis (PBC) and primary sclerosing cholangitis, as well as studies involving immunocompromised patient populations and asthma.

In these examples, Science 37 emphasizes its ability to contribute meaningful portions of total study enrollment, often in settings where eligible patients are geographically dispersed or where traditional recruitment methods face limitations. The company attributes these results to its Virtual Site and Patient Recruitment solutions, which it states can reach patients beyond the travel radius of conventional trial sites.

Technology platform and operational expertise

Science 37 repeatedly references a proprietary technology stack that underpins its Metasite™ and Patient Recruitment offerings. According to the company, this platform supports telemedicine visits, remote assessments, and standardized workflows for study orchestration. Science 37 also highlights its in-house medical and operational experts, including research-grade nursing and project delivery teams, as key components of its service model.

The company states that this combination of technology and expertise is intended to improve consistency, speed, and quality in patient recruitment and study conduct, while maintaining regulatory compliance. It also notes that its operations are organized to support collaboration across teams, which it associates with more integrated solution delivery for clinical trial sponsors.

Corporate location and facilities

Science 37 has announced the opening of a corporate headquarters in Morrisville, North Carolina, in the Research Triangle Park area. The company describes this facility as a central hub for operations, designed to enable cross-functional collaboration and to support patient recruitment and study conduct activities on behalf of clinical trial sponsors. This location aligns with the company’s broader emphasis on combining technology, clinical expertise, and operational capacity in a single, coordinated framework.

Position within the testing laboratories and clinical research ecosystem

Within the broader professional, scientific, and technical services sector, Science 37 positions itself as a company focused on clinical research enablement and testing-related activities in the context of clinical trials. Its disclosures emphasize patient access, decentralized or virtual site models, and the ability to support sponsors and CROs facing enrollment and operational challenges. Rather than functioning as a traditional brick-and-mortar trial site network, Science 37 highlights its role as a virtual or direct-to-patient site and as a recruitment partner that can be layered onto existing site infrastructures.

Use cases for sponsors and partners

Science 37 describes several ways in which sponsors and CROs can engage with its services:

• Adding Science 37 to under-enrolling or lagging studies to supplement recruitment and enrollment activities.
• Using the Metasite™ as a Virtual Site to enable patient participation from home or local community providers.
• Engaging Patient Recruitment as a standalone service to identify, medically qualify, and enroll patients across broad geographies.
• Combining the Metasite™ and Patient Recruitment into an integrated offering aimed at accelerated patient access and study execution.

Across these use cases, the company maintains a consistent focus on expanding access to clinical research, supporting diverse and geographically dispersed patient populations, and contributing to the speed and quality of clinical trial execution.

FAQs about Science 37 (SNCE)